Comparative Pharmacology
Head-to-head clinical analysis: NEMBUTAL SODIUM versus SECOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEMBUTAL SODIUM versus SECOBARBITAL SODIUM.
NEMBUTAL SODIUM vs SECOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing neuronal inhibition. Depresses the reticular activating system at higher doses.
Secobarbital enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion influx and causing neuronal hyperpolarization, leading to CNS depression.
30 mg IV or IM every 6 to 8 hours as needed for sedation; 65 to 100 mg IV or IM for hypnosis; 200 to 500 mg IV or IM for anticonvulsant effect in status epilepticus. Maximum single dose 500 mg.
Oral: 100-200 mg at bedtime for insomnia; IM: 150-200 mg as a single dose; IV: 50-250 mg as a single dose, administered slowly (not to exceed 50 mg per 15 seconds).
None Documented
None Documented
Terminal elimination half-life: 15-40 hours in adults; clinically relevant for accumulation with repeated dosing, especially in hepatic impairment.
Terminal elimination half-life is approximately 15-40 hours (mean ~30 hours) in adults. In neonates, half-life may be prolonged (up to 100 hours). Half-life increases in hepatic impairment and with advanced age.
Renal: ~25% unchanged; hepatic metabolism to inactive metabolites; ~50% excreted as metabolites in urine; biliary/fecal: minor.
Renal excretion of unchanged drug (about 25-50%) and metabolites; the remainder is eliminated via hepatic metabolism and fecal excretion. Less than 5% is excreted unchanged in feces.
Category C
Category D/X
Barbiturate
Barbiturate